Adrian van Den Hoffin, General Manager of Europe.
the Critical Medicines Law for the European Union (The European Union) is necessary for the security supply security. However, the law can only achieve its goals to reduce the deficiency and increase strategic self -government with adequate financing for manufacturing in Europe. This is the way they see from Medicines for EuropeThe European Generic employer, who considers this funding to be provided through various sources, including the European Union State Fund for Manufacturing Critical Drugs in the Future Multilateral Financial Framework (European Union budget) and regional aid.
Specifically, congratulations Public Health Committee From Parliament, through its recommendation, in the final opinion on “the report on a long -term renewable budget for the Union in a changing world” (2024/2051 (INI)), to include the European Union’s funds designated for the manufacture of critical drugs in the future financial framework (European Union budget). If it is with The most flexible standards in government aid Regional, this fund will enhance a new wave of investment in manufacturing in Europe.
“We ask now European Parliament Budget Committee This includes sufficient space for health and critical drugs in its final report. Looking at the amphitheated geopolitical situation and the need for open strategic autonomy, it is necessary to ensure Critical width medications To Europe, “he says.
Access to critical medications
the Critical Medicines Law It was presented in European Parliament Last month, he was enthusiastic about the pharmaceutical industry. However, too They have sent some “missions” to control them To reality. The European employer in this sector celebrates the efforts made to provide criteria that exceed the price of the general acquisition of critical drugs, but it requires the elimination of some barriers.
“a guarantee At the right time to reach critical medications It is a common priority. To achieve this, political solutions must be specific, based on evidence and compatible with international obligations to avoid unexpected consequences for the sustainability of the offer The patient’s arrivalHe emerges from the organization led by Natalie Mall.
Among the positive aspects of this regulations include the inclusion of reinformed cooperative acquisition options Improving the availability of medicines In certain circumstances. Although they believe that these options are suitable in very specific circumstances, as they accelerate patients’ access to critical medications, “their systematic application can be more harmful than providing a more permanent solution to reach problems.” For these reasons, they are more clearly betting on identifying these conditions in which cooperative acquisition options can improve “after the current national methods of Prices and money recovery“.
The information published in the medical writing contains data, data and data from official institutions and health professionals. However, given any questions related to your health, consult the opposite health specialist.
